The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors
- PMID: 7850714
- DOI: 10.1002/1097-0142(19950301)75:5<1151::aid-cncr2820750515>3.0.co;2-q
The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors
Abstract
Background: This report describes the development and validation of a brain subscale for the Functional Assessment of Cancer Therapy (FACT) scale, and the revalidation of the subscales of the general version (FACT-G), which measure physical, social, family, emotional, and functional well-being and the quality of the relationship with the physician.
Methods: 101 patients with primary brain tumors, after giving informed consent, participated in the last two phases of a four-phase validation process: item generation, item reduction, validation, and reliability testing. In the validation phase, FACT-G subscale and total scores as well as the brain subscale scores were correlated with other tests of mood, response, bias, and quality of life (QOL). Test-retest reliability testing was performed with 46 patients who had primary brain tumors.
Results: Validity and reliability coefficients were high for the FACT-G and brain subscale, except for the comparison with a second QOL measure (FP-QLI) and the Karnofsky Performance Status (KPS). The lower scores were the result of inherent differences in the two QOL instruments and the relatively high performance status of the brain tumor patients, which restricted the KPS score range.
Conclusion: The FACT-G has good psychometric properties supporting its broad generalizability and the brain subscale tests substantially different QOL issues than the core instrument. Use of this scale with the addition of the brain subscale provides a well rounded view of the various aspects of QOL from the patient's perspective. With modifications and further psychometric testing, the brain subscale may have broader applicability to subpopulations of patients with other brain disorders.
Similar articles
-
Psychometric validation of the functional assessment of cancer therapy--brain (FACT-Br) for assessing quality of life in patients with brain metastases.Support Care Cancer. 2014 Apr;22(4):1017-28. doi: 10.1007/s00520-013-2060-8. Epub 2013 Nov 28. Support Care Cancer. 2014. PMID: 24287508
-
Development and validation of the disease-specific QOL-CD quality of life questionnaire for patients with Cushing's disease.Neurosurg Focus. 2020 Jun;48(6):E4. doi: 10.3171/2020.3.FOCUS2044. Neurosurg Focus. 2020. PMID: 32480368
-
Development and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument.Qual Life Res. 1996 Aug;5(4):450-63. doi: 10.1007/BF00449920. Qual Life Res. 1996. PMID: 8840825
-
Outcomes and patient-based hearing status in conductive hearing loss.Laryngoscope. 2001 Nov;111(11 Pt 2 Suppl 98):1-21. doi: 10.1002/lary.5541111401. Laryngoscope. 2001. PMID: 11802001 Review.
-
Reliability, validity and feasibility of quality of life instruments for adult patients with cancer undergoing chemotherapy: result from a systematic review.Int J Evid Based Healthc. 2012 Mar;10(1):27-52. doi: 10.1111/j.1744-1609.2012.00252.x. Int J Evid Based Healthc. 2012. PMID: 22405415 Review.
Cited by
-
Neuroanatomical profiles of cognitive phenotypes in patients with primary brain tumors.Neurooncol Adv. 2024 Aug 29;6(1):vdae152. doi: 10.1093/noajnl/vdae152. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39359697 Free PMC article.
-
Symptom burden, palliative care knowledge, and palliative care needs in advanced gynecological cancer patients in Korea.Support Care Cancer. 2024 Aug 10;32(9):582. doi: 10.1007/s00520-024-08772-0. Support Care Cancer. 2024. PMID: 39126487
-
Life with a lower-grade glioma: How can neuro-oncologists advance its understanding and management?Neurooncol Pract. 2024 May 10;11(3):223-225. doi: 10.1093/nop/npae031. eCollection 2024 Jun. Neurooncol Pract. 2024. PMID: 38737613 No abstract available.
-
Benefits, Harms, and Stakeholder Perspectives Regarding Opioid Therapy for Pain in Individuals With Metastatic Cancer: Protocol for a Descriptive Cohort Study.JMIR Res Protoc. 2024 Mar 13;13:e54953. doi: 10.2196/54953. JMIR Res Protoc. 2024. PMID: 38478905 Free PMC article.
-
PAM trial protocol: a randomised feasibility study of psychedelic microdosing-assisted meaning-centred psychotherapy in advanced stage cancer patients.Pilot Feasibility Stud. 2024 Feb 12;10(1):29. doi: 10.1186/s40814-024-01449-9. Pilot Feasibility Stud. 2024. PMID: 38347582 Free PMC article.
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical